Welcome to Markets Desk, here's what's moving the needle this hour.
Michael Burry, the contrarian investor immortalized in The Big Short, is pushing back hard against the AI establishment. Burry says calls from Sam Altman, Dario Amodei, and other AI chiefs for slower development are, in his words, self-serving, arguing that humanity has nothing to fear and that these leaders are simply protecting their own competitive positions.
Shifting to pharmaceuticals, Novo is dropping the Nordisk from its corporate name in a deliberate rebranding move aimed squarely at Eli Lilly. The Danish giant behind Ozempic is signaling it wants a leaner, sharper identity as competition in the weight-loss drug market intensifies. This is a brand war as much as a science war, and Novo wants to look the part.
And in the entrepreneurial space, a story worth noting. Ashley Tyrner-Dolce was on food stamps while pregnant and went on to build a produce subscription business that sold for forty-seven point five million dollars. Her daughter, who held stock in the company, now has millions held in trust. It is a reminder that origin stories in business rarely look like the ending.
That's the tape. Markets Desk, signing off the floor.
